Megestrol acetate versus aminoglutethimide for metastatic breast cancer
- 28 Downloads
In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment>8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).
Key wordsadvanced breast cancer second-line endocrine therapy megestrol acetate aminoglutethimide
Unable to display preview. Download preview PDF.
- 1.Beatson GT: Oophorectomy in advanced breast cancer in young women. Lancet II: 104, 1896Google Scholar
- 2.Macaulay V, Smith IE: Advanced breast cancer. In: ML Slevin, MJ Staquet (eds) Randomized trials in cancer. A critical review by sites. Vol 15. Raven Press, New York, 1986, pp 273–357Google Scholar
- 4.Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal women with advanced breast cancer. J Clin Oncol 4: 1236–1240, 1986Google Scholar
- 5.Stoll BA: Combination endocrine therapy — concurrent or sequential? In: BA Stoll (ed) Endocrine management of cancer. 2. Contemporary therapy. Karger, Basel, pp 80–101, 1988Google Scholar
- 9.Kvinnsland S, Lønning PE, Dahl O: Treatment of breast carcinoma with aminoglutethimide. Acta Radiologica Oncologica 23: 421–424, 1984Google Scholar
- 11.Smith IE: Decision making in palliative therapy. In: BA Stoll (ed) Breast cancer. Treatment and prognosis. Blackwell Scientific Publications, Oxford, pp 86–97, 1986Google Scholar
- 12.Paterson AHG: Systemic therapy — prolonged survival or growth control. Ibid, pp 29–44, 1986Google Scholar
- 15.Morgan LR: Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol XII (suppl 1): 43–47, 1985Google Scholar
- 16.Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Stuart JJ, Richards II F, White DR, Zekan PJ, Spurr CL, Pope E, Case D, Morgan T, Wells B: Megestrol acetate v tamoxifen in advanced breast cancer: A phase III trial of the Piedmont Oncology Association (POA). Semin Oncol XII (Suppl 1): 55–61, 1985Google Scholar
- 18.Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432–1434, 1981Google Scholar
- 19.Harris AL, Cantwell BMJ, Sainsbury JR, Needham G, Evans RGB, Dawes PJDK, Wilson R, Farndon J: Lowdose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. Breast Cancer Res Treat (Suppl) 7: 41–44, 1986Google Scholar